Recent News

• 05.15.2025 - Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
• 05.15.2025 - Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
• 05.13.2025 - Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
• 05.08.2025 - Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
• 05.08.2025 - Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
• 05.01.2025 - Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
• 05.01.2025 - Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
• 04.30.2025 - Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
• 04.30.2025 - Cidara Therapeutics to Participate in The Citizens Life Sciences Conference

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - 3 Initial statement of beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 8-K Current report
• 05.08.2025 - S-3 Registration statement under Securities Act of 1933